Market Currents
Pharmasset (VRUS +10.7%) jumps after announcing earlier it's initiated Phase 3 studies for its...
-
Tuesday, November 1, 2011, 3:04 PM ETPharmasset (VRUS +10.7%) jumps after announcing earlier it's initiated Phase 3 studies for its hepatitis C virus nucleotide analog, PSI-7977.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
